RespireRx Pharmaceuticals Inc (fka RSPI)

[gfp927z]

Aiming, I think we might be surprised at the amount of buyout interest. Lilly and Glaxo both have AMPA upmodulation programs (Lilly's biarylpropylsulfonamide compounds having had a lot of problems), and both are challenging Cortex's broad use cognition patent in Europe (Lilly having failed in its first attempt). Aventis also has patented some AMPA upmodulators, and Boehringer Ingelheim has also. Organon is now owned by Schering, so they have some AMPA properties, and Hassan might conceivably be interested. And former partner Servier also continues with AMPA work. Other BPs with dwindling pipelines might also be interested.

As we know, Cortex owns the broad use patents for Cognition/Memory, Neurotrophin Upregulation (the high impact mode of action), Schizophrenia, combo uses with ACHase inhibitors, Respiratory Depression, endocrine modulation, sexual dysfunction, and others. As Neuro said, control by one company of broad use patents like these is very unusual in the pharma world.

(continued)